20 Years of AMD Leadership

2001: The First Age
Related Eye Disease
Study (AREDS)

NEI researchers concluded their first
five-year clinical Age Related Eye Disease
Study (AREDS).

4,757

Study participants ages 55
to 80 years, with and
without AMD.

19%

Reduced risk of moderate
vision loss after five years.

25%

Reduction in risk of AMD
progression in those with
moderate to advanced
AMD.

10 Years

Participants showed
continued effects at
study follow-up in 2006.

2013: AREDS2, the
2nd Age Related Eye
Disease Study

Based on new learnings around AMD, the
NEI researchers sought to improve the
original AREDS formula.

The result was an updated formula that replaced beta-carotene with lutein and zeaxanthin, since new research suggested an association between beta-carotene and an increase in the risk of lung cancer among those with a history of smoking.2

4,203

Study participants ages 50
to 85, with AMD.

82

Clinical centers across the
U.S.

5 Years

Length of AREDS2 study.

18%

Reduced risk of
progressing to advanced
AMD, compared to
patients taking the
original AREDS
formulation.1

  1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis
  2. Johnson EJ. Curr Opin Clin Nutr Metab Care. 2010;13(1):28-33

1. No clinically statistically significant differences in AEs between treatment groups. Post-hoc subgroup analysis
2. Johnson EJ. Curr Opin Clin Nutr Metab Care. 2010;13(1):28-33

2022: The AREDS2 10 Year Follow-On Study

The NEI publishes the results of its 10 Year Follow-on
study1, using Bausch + Lomb’s PreserVision®
AREDS 2 Formula Eye Vitamins in the last 5
years of study.


The NEI’s AREDS2 10 year Follow-on study
further validated the original findings about
the AREDS2 formulation with 80mg of zinc.
The study also provided support for the
continued benefit of lutein and zeaxanthin vs.
beta-carotene.


Read More

6,360

Eyes in the NEI AREDS2 10
year follow-on study

10%

Reduction in progression
to late AMD

20%

Reduction in progression
to neovascular AMD

10

10 Years of sustained
results


  1. Chew, Emily Y., et al. JAMA Ophthalmol. Published online June 2, 2022. doi:10.1001/jamaophthalmol.2022.1640
Today

The NEI recommends taking a vitamin formula that contains the exact nutrients based on the AREDS2 study for helping to reduce the risk of progression in moderate to advanced AMD.

Nutrient Amount (per day) Percent Daily Value
Zinc 80 mg 727%
Lutein 10 mg **
Zeaxanthin 2 mg **
Vitamin C 500 mg 556%
Vitamin E 180 mg 1200%
Copper 2 mg 222%

* Percent Daily Values (DV) Based on a 2000-calorie diet
**Daily value not established

Stay Tuned

Findings

Lutein + Zeaxanthin Vs. Beta-Carotene

Lutein + Zeaxanthin showed an approximate 20% beneficial effect vs beta-carotene, as well as no increased risk of lung cancer in patients who were former and current smokers.1

80mg Zinc Vs. “Low” Zinc

No significant side effects were observed in patients who received a formula with 80 mg zinc per day.
Therefore, the NEI continues to recommend 80mg zinc per the results of the AREDS2 10 year follow-on study.

EPA+DHA Vs. No Fatty Acid Supplementation

Recent data indicates no statistical beneficial effect in EPA+DHA towards reducing the risk of progression to late AMD in the AREDS2 formulation.

  1. Chew, E.Y, et al. 2022. The Long-term effects of adding Lutein-Zeaxanthin and Omega-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration. [Unpublished Manuscript] The AREDS2 Research Group/National Eye Institute.

PreserVision® Samples
for Your Appropriate Patients

Request Samples

*These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure or prevent any disease.

 

Based on the AREDS and AREDS2 clinical studies

*These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure or prevent any disease.

Text Size:A−A+